XYD198
XYD198 (Compound 14h) is an orally active degrader for CBP/p300. XYD198 inhibits CBP/p300 bromodomain with IC50 of 213.5 nM. XYD198 exhibits antitumor activity against acute myeloid leukemia. (Structure: Pink, CBP/p300 ligand 4 ; Blue, E3 ligase ligand (HY-14658) ; Black: linker (HY-161499) )
Product Specifications
UNSPSC
12352005
Target
Epigenetic Reader Domain; PROTACs
Type
Reference compound
Related Pathways
Epigenetics; PROTAC
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/xyd198.html
Solubility
10 mM in DMSO
Smiles
O=C1CCC[C@H](N1C2=CC=C(C(F)=C2)F)C3=NC4=C(C=CC(C5=C(ON=C5C)C)=C4)N3C6CCN(CC6)CC(NC7=CN=C(N=C7)C8=CC=C(C=C8)CNC9=CC=CC(C(N%10C%11C(NC(CC%11)=O)=O)=O)=C9C%10=O)=O
Molecular Formula
C54H49F2N11O7
Molecular Weight
1002.03
References & Citations
[1]Hu J, et al., Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity. J Med Chem. 2024 May 9;67 (9) :6952-6986.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RC203272L4V 200 µL
PEN2 (PSENEN) (NM_172341) Human Tagged ORF Clone Lentiviral Particle
Sign In for Pricing
View Details 
K1690104 1.0 µg DNA
POU2AF1 sgRNA CRISPR Lentivector (Human) (Target 3)
Sign In for Pricing
View Details